IMMU-38. TARGETING HYPOXIA DOWNSTREAM SIGNALING PROTEIN, CAIX FOR CAR-T CELL THERAPY AGAINST GLIOBLASTOMA (GBM)
Jing Cui, Zhengping Zhuang(National Cancer Institute), Herui Wang(National Institute of Neurological Disorders and Stroke), Yu Yao(Qinghai University), Timothy Westlake, Xiaoyu Cao(Chengdu University of Traditional Chinese Medicine), Mark R. Gilbert(Johns Hopkins University SAIS Bologna Center), Qi Zhang(Peking University), Kaiyong Yang(Nanjing University of Chinese Medicine), Qi Song(Macau University of Science and Technology), Jared S. Rosenblum(National Institutes of Health)
Cited by 0
Related Papers
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
|New England Journal of Medicine|2014|2.8k
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
|Neuro-Oncology|2020|1.1k
Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial
|Journal of Clinical Oncology|2013|1.1k
Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma
|New England Journal of Medicine|2016|1k
Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001
|Journal of Clinical Oncology|2020|827